Drug intelligence / Profile preview

Lacolite Z

Development stage: Unknown
Lead developer: ESKAG Pharma
Modality: Live Biotherapeutic Products → Microbiome Therapeutics, Small Molecules
Administration: Oral

Overview

Lacolite Z is an oral rehydration therapy developed by Eskag Pharma. It is formulated as a 3-in-1 comprehensive therapy for diarrhea and dehydration, combining a low-osmolarity oral rehydration salts (ORS) blend with probiotics and zinc. Each sachet contains essential electrolytes (sodium chloride, potassium chloride, and sodium citrate) and dextrose to restore fluid and electrolyte balance, zinc sulfate monohydrate to support immune health and reduce the duration and recurrence of diarrheal episodes, and a probiotic blend (Bacillus coagulans, Lactobacillus acidophilus, and Lactobacillus rhamnosus) to help restore healthy gut microflora and support gastrointestinal recovery.

Brand names: Lacolite Z
Other names: Lacolite-Z

Targets

SLC5A1 (Sodium Glucose Cotransporter 1)

Beyond the preview

Go deeper on Lacolite Z.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lacolite Z.